Stem cell membrane-coated isotretinoin for acne treatment.
Acne Vulgaris
Administration, Cutaneous
Animals
Cell Membrane
/ chemistry
Dermatologic Agents
/ administration & dosage
Disease Models, Animal
Drug Carriers
/ chemistry
Human Umbilical Vein Endothelial Cells
/ cytology
Humans
Isotretinoin
/ administration & dosage
Male
Mesocricetus
Nanoparticles
Rabbits
Skin
/ drug effects
Skin Absorption
Stem Cells
/ cytology
Acne
Isotretinoin
Nanoparticles
Stem cell
Transdermal
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
28 Jul 2020
28 Jul 2020
Historique:
received:
26
03
2020
accepted:
20
07
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
1
5
2021
Statut:
epublish
Résumé
Topical isotretinoin is commonly used to treat acne. However, topical isotretinoin has side effects and can hardly permeate through the stratum corneum, the most important skin barrier. Therefore, this study aimed to demonstrate the efficacy of nanoparticles as stable carriers with great curative effects, low side effects, and strong transdermal ability. In a rabbit model of hyperkeratinization, STCM-ATRA-NPs showed significant therapeutic efficacy. By contrast, negative therapeutic efficacy was observed in a golden hamster model of hyper sebum production. Scanning electron microscopy and Fourier transform infrared spectral analyses showed that nanoparticles could penetrate the stratum corneum. Western blotting demonstrated that the nanoparticles could enhance the transdermal efficacy of isotretinoin by reducing the effect of keratin and tight junction proteins. Further, nanoparticles enhanced endocytosis, thereby promoting drug penetration and absorption into the skin. STCM-ATRA-NPs were demonstrated to control isotretinoin release, reducing its side effects, and efficiently permeating through the skin by reducing the effect of keratin and tight junction proteins and enhancing endocytosis.
Sections du résumé
BACKGROUND
BACKGROUND
Topical isotretinoin is commonly used to treat acne. However, topical isotretinoin has side effects and can hardly permeate through the stratum corneum, the most important skin barrier. Therefore, this study aimed to demonstrate the efficacy of nanoparticles as stable carriers with great curative effects, low side effects, and strong transdermal ability.
RESULTS
RESULTS
In a rabbit model of hyperkeratinization, STCM-ATRA-NPs showed significant therapeutic efficacy. By contrast, negative therapeutic efficacy was observed in a golden hamster model of hyper sebum production. Scanning electron microscopy and Fourier transform infrared spectral analyses showed that nanoparticles could penetrate the stratum corneum. Western blotting demonstrated that the nanoparticles could enhance the transdermal efficacy of isotretinoin by reducing the effect of keratin and tight junction proteins. Further, nanoparticles enhanced endocytosis, thereby promoting drug penetration and absorption into the skin.
CONCLUSION
CONCLUSIONS
STCM-ATRA-NPs were demonstrated to control isotretinoin release, reducing its side effects, and efficiently permeating through the skin by reducing the effect of keratin and tight junction proteins and enhancing endocytosis.
Identifiants
pubmed: 32723398
doi: 10.1186/s12951-020-00664-9
pii: 10.1186/s12951-020-00664-9
pmc: PMC7390190
doi:
Substances chimiques
Dermatologic Agents
0
Drug Carriers
0
Isotretinoin
EH28UP18IF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106Subventions
Organisme : Department of Science and Technology of Jilin Province
ID : 20170414056GH
Organisme : Youth Program of National Natural Science Foundation of China
ID : 51703077
Commentaires et corrections
Type : ErratumIn
Références
Nat Med. 2013 Jan;19(1):35-42
pubmed: 23296015
Drug Deliv. 2015;22(6):731-9
pubmed: 24670094
Mol Pharm. 2017 Jun 5;14(6):1998-2009
pubmed: 28409629
Annu Rev Biochem. 2009;78:857-902
pubmed: 19317650
PLoS Genet. 2014 Oct 23;10(10):e1004706
pubmed: 25340345
Int J Pharm. 2008 Mar 20;352(1-2):123-8
pubmed: 18093761
Adv Mater. 2018 Feb;30(7):
pubmed: 29315905
Int J Mol Sci. 2018 Jul 23;19(7):
pubmed: 30041452
ACS Appl Mater Interfaces. 2018 Jul 11;10(27):22963-22973
pubmed: 29905067
J Exp Med. 2009 Dec 21;206(13):2937-46
pubmed: 19995951
J Control Release. 2016 Nov 28;242:105-118
pubmed: 27521894
Small. 2016 Aug;12(30):4056-62
pubmed: 27337109
Toxicol Appl Pharmacol. 1981 Jul;59(3):555-63
pubmed: 7268778
J Nanobiotechnology. 2017 Dec 04;15(1):88
pubmed: 29202753
J Am Acad Dermatol. 1988 Sep;19(3):486-91
pubmed: 2971693
Cell Transplant. 2016;25(5):829-48
pubmed: 26423725
J Pharm Biomed Anal. 2001 Dec;26(5-6):909-17
pubmed: 11600303
Cell. 2000 Jan 7;100(1):157-68
pubmed: 10647940
J Control Release. 2017 Sep 28;262:1-9
pubmed: 28690160
JAMA. 2004 Aug 11;292(6):726-35
pubmed: 15304471
Eur J Pharm Sci. 2008 Aug 7;34(4-5):203-22
pubmed: 18572392
Am J Clin Dermatol. 2012 Dec 1;13(6):357-64
pubmed: 22920095
ACS Appl Mater Interfaces. 2016 Dec 21;8(50):34252-34260
pubmed: 27936561
JAMA. 2014 May;311(20):2121-2
pubmed: 24867015
N Engl J Med. 2018 Oct 04;379(14):1343-1352
pubmed: 30281982
J Control Release. 2016 Nov 28;242:126-140
pubmed: 27620074
Lancet. 1998 Jun 20;351(9119):1871-6
pubmed: 9652685
Cell. 2016 Feb 11;164(4):595-7
pubmed: 26871623
Lancet. 2012 Jan 28;379(9813):361-72
pubmed: 21880356
J Invest Dermatol. 2018 Jun;138(6):1268-1278
pubmed: 29317263
Nat Rev Dis Primers. 2015 Sep 17;1:15029
pubmed: 27189872
J Control Release. 2015 Feb 10;199:168-78
pubmed: 25499919